Skip to main content
. Author manuscript; available in PMC: 2014 Oct 29.
Published in final edited form as: Cochrane Database Syst Rev. 2004;(1):CD001884. doi: 10.1002/14651858.CD001884.pub2
Methods Method of randomisation was not described. Study drugs were supplied in numbered but otherwise identical vials (Ferring Pharmaceuticals, Feltham, Middlesex, UK)
Participants 100 patients undergoing elective cardiopulmonary bypass for coronary artery bypass graft surgery were randomly assigned to one of two groups

  1. Desmopressin (DDAVP) group: n = 49; M/F = 42/7; mean age (+/−SD) = 58.8 (8.8) years.

  2. Placebo group: n = 49; M/F = 38/7; mean age (+/−SD) = 55.0 (8.4) years.
Interventions

  1. DDAVP group received 0.3 ug/kg of DDAVP intravenously over a period of 30 minutes at the end of cardiopulmonary bypass (CPB) and following the reversal of heparin by protamine sulphate.

  2. Placebo group received an unspecified solution.
Outcomes Number of patients transfused allogeneic blood (n)
Amount of allogeneic blood transfused (units)
Blood loss (ml)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method of randomisation was not described.
Allocation concealment? Yes A - Adequate
Blinding?
All outcomes		 Yes Double blind.